Molecular Partners Ag (MOLN) Enterprise Value (QoQ) (2021 - 2026)
Molecular Partners Ag (MOLN) Enterprise Value (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -666.56% |
| Dec 31, 2025 | 89.96% |
| Sep 30, 2025 | -231.89% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2025 | -52,954.76% |
| Dec 31, 2024 | 99.78% |
| Sep 30, 2024 | -43,474.30% |
| Jun 30, 2024 | 99.78% |
| Mar 31, 2024 | -37,064.42% |
| Dec 31, 2023 | 99.73% |
| Sep 30, 2023 | -31,810.78% |
| Jun 30, 2023 | 99.70% |
| Mar 31, 2023 | -30,806.92% |
| Dec 31, 2022 | 99.64% |
| Sep 30, 2022 | -24,284.72% |
| Jun 30, 2022 | 99.81% |
| Mar 31, 2022 | -106,664.67% |
| Dec 31, 2021 | 99.84% |
| Sep 30, 2021 | -64,954.37% |